Evidence map›Paper›PMID 27634912›Full record

ArticleOncotarget2016

Oncogenic microRNA-4534 regulates PTEN pathway in prostate cancer.

Hannah Nip, Altaf A Dar, Sharanjot Saini, Melissa Colden, Shahryari Varahram, Harshika Chowdhary, Soichiro Yamamura, Yozo Mitsui, Yuichiro Tanaka, Taku Kato and 10 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 1 country.

Hannah NipDepartment of Urology, VA Medical Center and UCSF, San Francisco, California, USA.
Altaf A DarResearch Institute, California Pacific Medical Center, San Francisco, California, USA.
Sharanjot SainiDepartment of Urology, VA Medical Center and UCSF, San Francisco, California, USA.
Melissa ColdenDepartment of Urology, VA Medical Center and UCSF, San Francisco, California, USA.
Shahryari VarahramDepartment of Urology, VA Medical Center and UCSF, San Francisco, California, USA.
Harshika ChowdharyDepartment of Urology, VA Medical Center and UCSF, San Francisco, California, USA.
Soichiro YamamuraDepartment of Urology, VA Medical Center and UCSF, San Francisco, California, USA.
Yozo MitsuiDepartment of Urology, VA Medical Center and UCSF, San Francisco, California, USA.
Yuichiro TanakaDepartment of Urology, VA Medical Center and UCSF, San Francisco, California, USA.
Taku KatoDepartment of Urology, VA Medical Center and UCSF, San Francisco, California, USA.
Yutaka HashimotoDepartment of Urology, VA Medical Center and UCSF, San Francisco, California, USA.
Marisa ShiinaDepartment of Urology, VA Medical Center and UCSF, San Francisco, California, USA.
Priyanka KulkarniDepartment of Urology, VA Medical Center and UCSF, San Francisco, California, USA.
Pritha DasguptaDepartment of Urology, VA Medical Center and UCSF, San Francisco, California, USA.
Mitsuho Imai-SumidaDepartment of Urology, VA Medical Center and UCSF, San Francisco, California, USA.
Z Laura TabatabaiDepartment of Urology, VA Medical Center and UCSF, San Francisco, California, USA.
Kirsten GreeneDepartment of Urology, VA Medical Center and UCSF, San Francisco, California, USA.
Guoren DengDepartment of Urology, VA Medical Center and UCSF, San Francisco, California, USA.
Rajvir DahiyaDepartment of Urology, VA Medical Center and UCSF, San Francisco, California, USA.
Shahana MajidDepartment of Urology, VA Medical Center and UCSF, San Francisco, California, USA.
San Francisco VA Medical Center · USCalifornia Pacific Medical Center · US

Funding

MicroRNAs in the Progression and Metastisis of Prostate CancerR01CA138642 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DAHIYA, RAJVIR · 2010 to 2014
$2.6M
Chemo-dietary prevention, miRNAs, epigenetic and prostate cancerR01CA160079 · NCI · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI DAHIYA, RAJVIR · 2011 to 2015
$2.2M
Genetic factors for race related prostate cancer.U01CA184966 · NCI · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI DAHIYA, RAJVIR · 2015 to 2019
$1.6M
BLRD VA I01 BX001123BLRD VA IK6 BX004473BLRD VA IP1 BX001604NCI NIH HHS R01 CA138642NCI NIH HHS R01 CA160079NCI NIH HHS U01 CA184966
6 · The paper itself

Abstract

Prostate carcinogenesis involves alterations in several signaling pathways, the most prominent being the PI3K/AKT pathway. This pathway is constitutively active and drives prostate cancer (PCa) progression to advanced metastatic disease. PTEN, a critical tumor and metastasis suppressor gene negatively regulates cell survival, proliferation, migration and angiogenesis via the PI3K/Akt pathway. PTEN is mutated, downregulated/dysfunctional in many cancers and its dysregulation correlates with poor prognosis in PCa. Here, we demonstrate that microRNA-4534 (miR-4534) is overexpressed in PCa and show that miR-4534 is hypermethylated in normal tissues and cell lines compared to PCa tissues/cells. miR-4534 exerts its oncogenic effects partly by downregulating the tumor suppressor PTEN gene. Knockdown of miR-4534 impaired cell proliferation, migration/invasion and induced G0/G1 cell cycle arrest and apoptosis in PCa. Suppression of miR-4534 and its effects on tumor growth was confirmed in a xenograft mouse model. We performed parallel experiments in non-cancer RWPE1 cells by overexpessing miR-4534 followed by functional assays. Overexpression of miR-4534 induced pro-cancerous characteristics in this non-cancer cell line. Statistical analyses revealed that miR-4534 has potential to independently distinguish malignant from normal tissues and positively correlated with poor overall and PSA recurrence free survival. Taken together, our results show that depletion of miR-4534 in PCa induces a tumor suppressor phenotype partly through induction of PTEN. These results have important implications for identifying and defining the role of new PTEN regulators such as microRNAs in prostate tumorigenesis. Understanding aberrantly overexpressed miR-4534 and its downregulation of PTEN will provide mechanistic insight and therapeutic targets for PCa therapy.

Indexed as

Gene Expression Regulation, Neoplastic3' Untranslated RegionsAgedAged, 80 and overAnimalsApoptosisCell LineCell Line, TumorCell MovementDNA MethylationG1 Phase Cell Cycle CheckpointsGene Knockdown TechniquesHumansMaleMice, NudeMicroRNAs3' Untranslated RegionsMicroRNAsPTEN PhosphohydrolasePTEN protein, humanmicroRNAmiR-4534oncogeneprostate cancerPTEN

Identifiers

PMID27634912
PMCPMC5356562
OpenAlexW2519190573

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.